Literature DB >> 108269

Metabolism of prostaglandin D2 in the monkey.

C K Ellis, M D Smigel, J A Oates, O Oelz, B J Sweetman.   

Abstract

[3H7]Prostaglandin D2 was biosynthesized and infused into an unanesthetized monkey. The urinary metabolites were isolated and subsequently identified by gas chromatography-mass spectrometry. Two pathways of prostaglandin D2 metabolism were identified and resulted in metabolites with prostaglandin D (3-hydroxycyclopentanone) and prostaglandin F (cyclopentane-1,3-diol) ring structures. The major prostaglandin D ring metabolite was identified as 9,20-dihydroxy-11,15-dioxo-2,3-dinorprost-5-en-1-oic acid. Nine other prostaglandin D ring metabolites were identified reflecting various combinations of metabolism by beta and omega oxidation, 15 dehydrogenation, and 13-14 reduction. In greater abundance were those prostaglandin D2 metabolites which had the prostaglandin F ring structure. The major prostaglandin D2 metabolite which had the prostaglandin F ring structure was identified as 9,11,15-trihydroxy-2,3-dinorprosta-5,13-dien-1-oic acid (dinor prostaglandin F2 alpha). Nine other metabolites with the prostaglandin F ring structure were identified, including prostaglandin F2 alpha itself. These, for the most part, were the structural counterparts of the metabolites with the prostaglandin D ring. Since many prostaglandin D2 metabolites were found to be identical with the metabolites of prostaglandin F2 alpha, quantitative determinations of prostaglandin F ring metabolites may not be a specific indicator of prostaglandin F2 alpha biosynthesis. Likewise, data involving the measurement of a biological effect of prostaglandin D2 must be re-examined to account for the possible contribution of prostaglandin F2 alpha, a metabolite of prostaglandin D2, to the biological response.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 108269

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Prostaglandin D2, a neuromodulator.

Authors:  T Shimizu; N Mizuno; T Amano; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  Identification of 13,14-dihydro-15-oxo-prostaglandin F2 alpha in the circulation during infusions of bradykinin and prostaglandin E2 in man.

Authors:  S E Barrow; J Cockcroft; C T Dollery; N E Hickling; J M Ritter
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

3.  Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandins E2 and F2 alpha.

Authors:  U Förstermann; R Heldt; G Hertting
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

4.  9-Deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma.

Authors:  Y Kikawa; S Narumiya; M Fukushima; H Wakatsuka; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

5.  Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans.

Authors:  T E Liston; L J Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

6.  Evidence against the formation of 13,14-dihydro-15-keto-prostaglandin F2 alpha following inhalation of prostaglandin D2 in man.

Authors:  C C Hardy; S T Holgate; C Robinson
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

7.  Isomeric prostaglandin F2 compounds arising from prostaglandin D2: a family of icosanoids produced in vivo in humans.

Authors:  D F Wendelborn; K Seibert; L J Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

8.  9 alpha,11 beta-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways.

Authors:  C R Beasley; C Robinson; R L Featherstone; J G Varley; C C Hardy; M K Church; S T Holgate
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.